Effect of Topical and Intravenous Tranexamic Acid (TXA) on Thrombogenic Markers in Patients Undergoing Knee Replacement

Exclusion Criteria

• •All patients on steroid therapy regardless of dose, duration, or treatment or those requiring stress-dose steroids preoperatively
• •Patients who will require postoperative use of Coumadin, Xarelto, or Plavix
• •Use of non-steroidal anti-inflammatory drugs (NSAIDs) within 1 week of surgery
• •Hypersensitivity to tranexamic acid
• •Renal dysfunction (Creatinine clearance \< 40 ml/min)
• •Hepatic dysfunction (AST or ALT 2x upper limit of normal)
• •Cardiac exclusions: coronary stent, history of myocardial infarction, positive stress test, atrial fibrillation, advanced coronary artery disease
• •Advanced chronic obstructive pulmonary disease or advanced interstitial lung disease
• •History of venous thromboembolism
• •Hypercoagulability (e.g. antiphospholipid syndrome, genetic hypercoagulability with or without prior venous thromboembolism)
• •History of stroke or transient ischemic attack